Caredx Inc   (CDNA)
Other Ticker:  
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
Price: $10.6400 $0.92 9.465%
Day's High: $11.0899 Week Perf: 28.66 %
Day's Low: $ 8.23 30 Day Perf: 13.68 %
Volume (M): 3,482 52 Wk High: $ 12.93
Volume (M$): $ 37,047 52 Wk Avg: $8.84
Open: $9.73 52 Wk Low: $4.80

 Market Capitalization (Millions $) 572
 Shares Outstanding (Millions) 54
 Employees 446
 Revenues (TTM) (Millions $) 280
 Net Income (TTM) (Millions $) -190
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 1

Caredx Inc
CardeDX Inc. is a commercial-stage precision medicine company that specializes in developing clinically actionable diagnostics to advance the field of transplant medicine. The company is based in Brisbane, California, and was founded in 2011. Its products and services are aimed at improving patient outcomes by providing accurate and reliable information about their transplant status.

Caredx's primary focus is on providing organ transplant patients with the latest diagnostic tools to ensure the best possible patient outcomes. The company's products and services are designed to help clinicians predict the likelihood of transplant rejection, monitor transplant patients for potential complications, and provide personalized treatment plans to prevent organ rejection.

Caredx's flagship product, the AlloSuree test, is a blood test that measures the fraction of donor-derived cell-free DNA circulating in a transplant recipient's bloodstream. The test provides clinicians with valuable information about the health of transplanted organs and helps to identify whether a patient is rejecting the transplant. The AlloSure test is the first and only commercially available test of its kind, and it is currently available in the United States and select international markets.

In addition to the AlloSure test, Caredx also offers a range of other diagnostic solutions for transplant patients, including the AlloMape test, which measures the expression of genes associated with organ rejection, and the AlloSeqe HLA genotyping test, which helps to identify the compatibility between a donor and recipient.

Caredx's services are primarily used by transplant centers, hospitals, and transplant specialists. The company has established partnerships with many leading academic medical centers and transplant organizations in the United States and internationally.

The company has a strong focus on research and development and has invested heavily in building a cutting-edge laboratory facility that allows for the development and testing of novel transplant diagnostics. In addition to developing new products and services, Caredx also works closely with transplant centers and transplant professionals to educate them about the latest advances in transplant diagnostic technology.

Caredx has received numerous awards and recognitions for its innovative products and services, including the 2016 Frost & Sullivan Technology Innovation Award and the 2018 Red Herring Top 100 North America Award.

Overall, Caredx is a leading player in the fast-growing field of precision medicine and is at the forefront of driving innovation and advancement in transplant diagnostics. With a strong commitment to research and development, the company is well-positioned to continue to grow and expand its product offerings and contribute to improving patient outcomes in the field of transplant medicine.

   Company Address: 8000 Marina Boulevard Brisbane 94005 CA
   Company Phone Number: 287-2300   Stock Exchange / Ticker: NASDAQ CDNA


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Caredx Inc

Caredx Inc. Sees Double-Digit Revenue Decline Through Fiscal Year Ending December 31, 2023

The stock market can be a rollercoaster ride for investors, with its ups and downs and constant changes. However, it is important to remember that even in challenging times, there are always opportunities to be found. One company that has recently faced some setbacks is Caredx Inc. Despite reporting a rise in losses for the fourth quarter of 2023, there are several positive factors investors should consider.
In the financial report, Caredx Inc. disclosed a shortfall per share that inched up to $-2.18 from $-0.34. While this may seem concerning at first, it is important to note that this increase is primarily due to weak demand, rather than any fundamental issues with the company itself. It is crucial to analyze the root causes behind such setbacks in order to make informed investment decisions.

Caredx Inc

CDNA Reports Increased Deficit in Third Quarter 2023 Earnings Season compared to Last Year

Caredx Inc, a leading medical diagnostics company, has recently released its third-quarter earnings results for 2023. Unfortunately, the company's financial performance paints a bleak picture, with both earnings per share and revenue experiencing a decline compared to the previous year. This bearish article will analyze the company's poor financial performance, highlight its increasing net losses, and discuss the potential risks and challenges it may face in the near future.
Earnings Per Share Shows Minimal Improvement Amidst Worsening Deficit:
During the third quarter of 2023, the company's earnings deficit extended to $-0.43 per share, compared to $-0.32 per share during the same period the previous year. Although there was a nominal improvement from the preceding reporting season, where earnings per share stood at $-0.46, the continued deficit remains a concerning issue for Caredx Inc shareholders.

Caredx Inc

Caredx Inc Faces Financial Setback as Shortfall per Share Deepens, Threatening Future Growth

Caredx Inc recently released its financial results for the fiscal year ending June 30, 2023. The results reveal several interesting trends and figures that could potentially impact the company's future growth and prospects. This article delves into these findings and ponders how they might influence Caredx Inc in the coming months.
1. Increased Shortfall per Share:
Caredx Inc witnessed a rise in the shortfall per share, reaching $-0.46 compared to $-0.41 in the previous year. Moreover, compared to the prior financial reporting period, the shortfall grew from $-0.44 per share. This indicates that the company's profitability declined over the respective periods, potentially warranting a closer examination of its financial strategy.

Caredx Inc

Caredx Inc's Revenue Takes a Hit as Recent Fiscal Period Reveals a Decline

Caredx Inc, a healthcare company in the United States, has recently experienced a decline in its revenue per employee. The trailing twelve month basis shows that the revenue per employee has fallen to $716,679 from its previous rate. Nevertheless, the productivity of Caredx Inc's employees remains above the company's average, indicating that the decline in revenue may be due to other factors.
Caredx Inc currently has 446 employees, and among its peers within the healthcare sector, 76 other companies' employees have achieved higher revenue per employee. The company's overall ranking in the industry has also deteriorated compared to the fourth quarter of 2022, dropping to 76.


Caredx Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Caredx Inc does not provide revenue guidance.

Earnings Outlook
Caredx Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com